CIBC Asset Management Inc Acquires 65 Shares of United Therapeutics Co. (NASDAQ:UTHR)

CIBC Asset Management Inc lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,598 shares of the biotechnology company’s stock after acquiring an additional 65 shares during the period. CIBC Asset Management Inc’s holdings in United Therapeutics were worth $564,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in shares of United Therapeutics by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after acquiring an additional 45,566 shares during the period. FMR LLC lifted its holdings in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after acquiring an additional 314,004 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of United Therapeutics by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after acquiring an additional 30,931 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of United Therapeutics by 12.3% during the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock worth $164,978,000 after acquiring an additional 50,409 shares during the period. Finally, Assetmark Inc. lifted its holdings in shares of United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after acquiring an additional 152,249 shares during the period. 94.08% of the stock is owned by institutional investors.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $960,576.75. The trade was a 79.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 124,164 shares of company stock worth $45,398,793 in the last quarter. 11.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. LADENBURG THALM/SH SH increased their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Oppenheimer increased their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Trading Down 1.7 %

UTHR opened at $361.10 on Friday. The stock has a market capitalization of $16.12 billion, a PE ratio of 15.86, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 1-year low of $214.75 and a 1-year high of $417.82. The firm has a 50-day moving average price of $362.68 and a two-hundred day moving average price of $360.45.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.